Sign In
Buy ARCT
$6.71
-0.260 (-3.73%)
At Close: Jul 13, 2026
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
08:12am, Friday, 03'rd Jul 2026
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
11:32am, Thursday, 02'nd Jul 2026
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the com
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
08:00am, Thursday, 02'nd Jul 2026
Arcturus Therapeutics Holdings Inc. (âArcturusâ, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
07:00am, Thursday, 02'nd Jul 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory
Arcturus could halve the grid's electrical losses using its nano-infused copper
11:01am, Tuesday, 30'th Jun 2026
The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
01:42pm, Friday, 05'th Jun 2026
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
05:03am, Friday, 05'th Jun 2026
Arcturus Therapeutics NASDAQ: ARCT President and CEO Joseph Payne outlined the company's messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferi
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
04:01pm, Tuesday, 26'th May 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics will present at 2026 Jefferies Global Healthcare Conference.
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
12:31am, Friday, 08'th May 2026
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
06:55pm, Thursday, 07'th May 2026
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago.
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
04:01pm, Thursday, 07'th May 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
04:01pm, Monday, 27'th Apr 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
04:06am, Friday, 17'th Apr 2026
Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) by 88.5% in the fourth quarter, according to the company in its most recent Form 13F filing with
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:52am, Wednesday, 25'th Mar 2026
Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way f
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
02:39am, Wednesday, 25'th Mar 2026
Arcturus Therapeutics (NASDAQ: ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 va
